ASX - By Stock
|
EUR |
Re:
Ann: Options Prospectus
|
|
Bpharma
|
16 |
5.3K |
0 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
16
|
5.3K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
10 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
44
|
15K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
9 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
44
|
15K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
44
|
15K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
15K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
11 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
15K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
4 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
15K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bpharma
|
4 |
2.0K |
7 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
4
|
2.0K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
7 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
44
|
15K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
3 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
44
|
15K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
3 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
44
|
15K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
5 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
44
|
15K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
15K |
10 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
44
|
15K
|
10
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Annual Report to shareholders
|
|
Bpharma
|
36 |
9.9K |
4 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
36
|
9.9K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce gearing up for Indonesian trials
|
|
Bpharma
|
37 |
10K |
6 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
37
|
10K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Bpharma
|
22 |
7.8K |
9 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
22
|
7.8K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Bpharma
|
22 |
7.8K |
5 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
22
|
7.8K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Bpharma
|
22 |
7.8K |
20 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
22
|
7.8K
|
20
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
191 |
53K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
191
|
53K
|
0
|
|
ASX - By Stock
|
LMG |
Re:
general discussion
|
|
Bpharma
|
1.9K |
847K |
0 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
1.9K
|
847K
|
0
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Update on BBB 33 Evaluation and Bolling 4 Drilling
|
|
Bpharma
|
220 |
78K |
0 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
220
|
78K
|
0
|
|
ASX - By Stock
|
CND |
Re:
Ann: Additional deeper targets identified in Bonito Prospect
|
|
Bpharma
|
47 |
10K |
2 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
47
|
10K
|
2
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
191 |
53K |
4 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
191
|
53K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
2 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
191 |
53K |
2 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
191
|
53K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
CND |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
191 |
53K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
191
|
53K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
RCE General Discussion Topics
|
|
Bpharma
|
51 |
25K |
4 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
51
|
25K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
11K |
2 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
38
|
11K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
14 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
48
|
14K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
1 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
11K |
4 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
38
|
11K
|
4
|
|
ASX - By Stock
|
EUR |
Re:
Where is the bottom ?
|
|
Bpharma
|
15 |
3.4K |
4 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
15
|
3.4K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.4K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.4K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.4K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.4K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.4K |
1 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.4K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.4K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.4K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.4K |
6 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.4K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
11K |
5 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
38
|
11K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
11K |
1 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
38
|
11K
|
1
|
|
ASX - By Stock
|
LMG |
Re:
general discussion
|
|
Bpharma
|
1.9K |
847K |
1 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
1.9K
|
847K
|
1
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Change of Director's Interest Notice
|
|
Bpharma
|
35 |
10K |
3 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
35
|
10K
|
3
|
|
ASX - By Stock
|
EUR |
Re:
Ann: Critical Metals Corp. Completes Business Combination
|
|
Bpharma
|
370 |
97K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
370
|
97K
|
2
|
|
ASX - By Stock
|
EUR |
Re:
Ann: Reinstatement to Quotation
|
|
Bpharma
|
15 |
4.9K |
5 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
15
|
4.9K
|
5
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.2K |
339K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.2K
|
339K
|
3
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.2K |
339K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.2K
|
339K
|
0
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.2K |
339K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.2K
|
339K
|
0
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.2K |
339K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.2K
|
339K
|
0
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.2K |
339K |
6 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.2K
|
339K
|
6
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Change of Director's Interest Notice
|
|
Bpharma
|
22 |
6.3K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
22
|
6.3K
|
3
|
|